Treatment of skin, and wound repair, with thymosin beta 4
AssigneeRegenerx Biopharmaceuticals, Inc.
InventorsHynda K. Kleinman, Katherine M. Malinda, Allan L. Goldstein, Gabriel Sosne
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treatment of skin utilizing thymosin β4.
Claims21
A composition for topical administration to skin, comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3;
- human transforming growth factor β1, and a pharmaceutically acceptable topical vehicle.
A composition for topical administration to skin comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3;
- human vascular endothelial growth factor and a pharmaceutically acceptable topical vehicle.
A method for improving damage to the skin, the method comprising:
- applying topically to said damaged skin a composition comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3;
- and a pharmaceutically acceptable topical vehicle.
A method for improving damage to the skin, the method comprising:
- applying topically a composition comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3, human transforming growth factor β1, and a pharmaceutically acceptable topical vehicle.
A method for improving damage to the skin, the method comprising:
- applying topically a composition comprising a tissue regeneration promoting amount of human thymosin β4 of SEQ ID NO:3, human vascular endothelial growth factor, and a pharmaceutically acceptable topical vehicle.
A composition for topical treatment of skin, comprising a thymosin beta 4 of SEQ ID NO:3 and a vehicle acceptable for topical administration, further comprising transforming growth factor beta, vascular endothelial growth factor, or both.
Dependencies are inferred from the claim text.